The firm raised its full-year revenue guidance on expectations of growth in the range of 3 to 5 percent but it maintained its full-year EPS guidance.

The firm's shares rose to $62.17 at the close of Tuesday's trading on news that TPG and Blackstone had offered to take the firm private.

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

According to the FDA, the tubes are not being produced in conformity with good manufacturing practice and have led to false positive lead test results.

NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...

During a fireside chat at the RBC Healthcare Conference, Bio-Rad's CFO Roop Lakkaraju confirmed the firm's prior guide for 130 basis points of net tariff impact, which Connor McNamera, RBC's moderator ...

NEW YORK – Japan's Eiken Chemical, perhaps best known in the molecular biology space as the developer of the widely used loop-mediated isothemal nucleic acid amplification technology, has overhauled ...

The DOJ alleged Agendia submitted false claims to Medicare, Medicaid, and other government payors for its MammaPrint breast cancer test.